**CURRICULUM VITAE**

**Yuan Liu, Ph.D.** 🞟 **September 2024**

Dept. of Biostatistics and Bioinformatics, Emory University

Biostatistics and Bioinformatics Shared Resource at Whinship Cancer Institute

1518 Clifton Rd. Room 352, Atlanta GA 30322, USA

404-778-1989 (Office) 🞟 E-mail: [yliu31@emory.edu](mailto:yliu31@emory.edu)

**EDUCATION**

2008 Ph.D. Biostatistics, University of South Carolina, Columbia, SC, USA

2004 M.S. Mathematics, University of North Carolina at Wilmington, Wilmington, NC, USA

1998 B.S. Bioengineering National Huaqiao University, Fujian, China

**ACADEMIC APPOINTMENT**

2024 – Faculty Consultant for Biostatistics and Study Design in the Winship Cancer for Cancer Health Equity Research (WCCHER)

2022 – Director of the Biostatistics and Bioinformatics Core, Emory Lung P01

2020 – Research Associate Professor, Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA

2010 –2020 Research Assistant Professor, Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA

2008 –2010 Post-Doctoral Trainee, Division of Biostatistics and Epidemiology, Medical University of South Carolina, Charleston, SC

2006 –2008 Research Assistant, Department of Family and Preventive Medicine, School of Medicine, University of South Carolina, Columbia, SC

2004 –2006 Research Assistant, Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC

2002 – 2004 Teaching Assistant, Department of Mathematics, University of North Carolina at Wilmington, Wilmington, NC

**RESEARCH INTEREST**

* Cancer comparative effectiveness research by observational database.
* Causal inference by generalized propensity score approaches.
* Cancer Prognostic and Predictive biomarkers development and validation.
* Biomarker-based clinical trial design.
* Application areas: prostate cancer, breast cancer, lung cancer, head and neck cancer, radiation oncology, surgical oncology, immunotherapy therapy, dermatology.

**LEADERSHIP EXPERIENCE**

* Faculty Consultant for Biostatistics and Study Design in the Winship Cancer for Cancer Health Equity Research (WCCHER)
* Director of the Biostatistics and Bioinformatics Core in Emory Lung P01 (2022-2027)
* Senior faculty in Biostatistics Shared Resource at Winship Cancer Insititute take the leading effort in system optimization with streamlined workflow and enhanced communication and collaborations with other shared resources (e.g., centralized documentation system, clinical trial data processing workflow, NCDB research workflow, staff/RA mentorship/training, SAS macros development/updates). (2020 -)

**PROFESSIONAL SERVICE**

***Extramural – Statistical Reviewer for NIH and DoD***

2019 Reviewer for the DoD, CDMRP Prostate Cancer Research Program (PCRP).

2020 Reviewer for the DoD, CDMRP Prostate Cancer Research Program (PCRP).

2021 Reviewer for the DoD, CDMRP Prostate Cancer Research Program (PCRP).

2022 Referee to the Medical Research Council’s Clinical Academic Research Partnerships Panel in UK Research and Innovation (UKRI)

2022 Statistical Reviewer for the Cancer Biotherapeutics Development (CBD) SBIR/STTR at NIH

2023 Statistical Reviewer for the Cancer Biotherapeutics Development (CBD) SBIR/STTR at NIH

2023 Statistical Reviewer for the Exploratory Clinical Trials of Mind and Body Interventions (MB) at NIH

2023 Scientific Reviewer for Ovarian Cancer Research Program (OCRP) for the Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP).

2023 Statistical Reviewer for Prostate Cancer Research Program (PRCRP) for the Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP).

2024 Statistical Reviewer for the Cancer Biotherapeutics Development (CBD) SBIR/STTR at NIH

2024 Statistical Reviewer for the DoD, CDMRP Breast Cancer Research Program – Biomarker panel (BCRP).

2024 Statistical Reviewer for Centers of Biomedical Research Excellence (COBRE) Phase I (P20) at NIH

***Extramural – Journal reviewer and Editorial Board***

2024 -Editorial Board Member (Biostatistician) for the Journal of the American Society of Cytopathology (JASC)

2010- External Reviewer for journals - Statistics in Medicine; International Journal of Biostatistics; Spatial and Spatial-temporal Epidemiology; Cancer; BMC Medical Research Methodology; BMC Health Services Research; IEEE Journal of Biomedical and Health Informatics; Cancer Investigation; *Nature Cancer*; Frontier in Public Health;

***Intramural***

2011- Independent Biostatistics Reviewer for Clinical Trail Review Committee board at Winship Cancer Institute, Emory University (reviewed over **495** research protocols as of June 2024)

2013 Independent Reviewer for University Research Committee at Emory (responsible for awarding small, short-term research grants available to regular, full-time faculty of Emory University through a competitive selection process. )

2014 Independent Reviewer for the University Research Committee at Emory.

**BIBLIOGRAPHY** ([<https://www.ncbi.nlm.nih.gov/myncbi/1T5XEYLq7kXQA/bibliography/public/>](https://www.ncbi.nlm.nih.gov/myncbi/yuan.liu.22/bibliography/public/) )

\* Students advised/mentored

**✪** Contributed as the lead biostatistician (role: study design, data analysis, writing the manuscript, and addressing journal review)

**✩** Contributed as the senior biostatistician (role: same role as in lead biostatistician except data analysis was done by staff or student under my close guidance).

**§** Corresponding author.

* **Book Chapters**

1. Harvey, R. D., **Liu, Y.**, Owonikoko, T. K., & Ramalingam, S. S. (2023) Biomarker Based Clinical Trial Design in the Era of Genomic Medicine. In *Holland‐Frei Cancer Medicine* (pp. 1-7). <https://doi.org/10.1002/9781119000822.hfcm021.pub2>

* **Patent**

1. Wei Zhou, Adam Marcus, Melissa Gilbert-Ross, Xiuji Liu, **Yuan Liu**, Frank Schneider, Yijian Fan, and Rui Jin (2022). Targeting LKB1-Mutant Cancer Cells With Natural Killer Cells. *Application patent No. 63/430,762*. United States Patent and Trademark Office.

* **Statistical Methodology: Peer-reviewed**

1. Lawson, A. B., Williams, F. L., & **Liu, Y**. (**2007**). Some simple tests for spatial effects around putative sources of health risk. *Biom J, 49*(4), 493-504. [PMID: 17638283]
2. Ma, B., Lawson, A. B., & **Liu, Y.** (**2007**). Evaluation of Bayesian Models for Focused Clustering in Health Data. *Environmetrics, 18*(8), 871-887.
3. **Liu, Y.,** & Bottai, M. (**2009**). Mixed-effects models for conditional quantiles with longitudinal data. Int J Biostat, 5(1), Article 28. [PMID: 26204606]
4. **Liu, Y.**, Lawson, A. B., Ma, B., & Bottai, M. (**2009**). Evaluation of Putative Hazard Tests under Background Risk Heterogeneity. *Environmetrics, 20*(3), 260-274.
5. **Liu, Y.**, McDermott, S., Lawson, A., & Aelion, C. M. (**2010**). The relationship between mental retardation and developmental delays in children and the levels of arsenic, mercury and lead in soil samples taken near their mother's residence during pregnancy. *Int J Hyg Environ Health, 213*(2), 116-123. [PMID: 20045663]
6. Tighiouart, M., **Liu, Y.**, & Rogatko, A. (**2014**). Escalation with overdose control using time to toxicity for cancer phase I clinical trials. *PLoS One, 9*(3), e93070. [PMID: 24663812]
7. **Liu, Y.**, Nickleach, D, Zhang, C., Switchenko, J., Kowalski, J. (**2018**). Carrying out streamlined routine data analyses with reports for observational studies: introduction to a series of generic SAS® macros. *F1000Res, 7*:1955. DOI: 10.12688/f1000research.16866.1. License: CC BY4.0. [PMID: 31231506].
8. Li, H., **Liu, Y.,** & Luo, Y. (**2020**). Double Penalized Quantile Regression for the Linear Mixed Effects Model. *Journal of Systems Science and Complexity, 33*(6), 2080-2102. doi:10.1007/s11424-020-9065-4
9. **Liu, Y.,** Patel, S. A., Jani, A. B., Gillespie, T. W., Patel, P. R., Godette, K. D., . . . McDonald, M. W. (**2020**). Overall Survival After Treatment of Localized Prostate Cancer With Proton Beam Therapy, External-Beam Photon Therapy, or Brachytherapy. Clin Genitourin Cancer. PMID: 32972877.
10. Kulkarni, S. E., Patel, S. A., Sun, Y., Jani, A. B., Gillespie, T. W., McDonald, M. W., & **Liu, Y**. **§** (**2024**). Secondary Cancer in Prostate Cancer Patients Treated With Advanced External Beam Radiation Therapy. *International Journal of Particle Therapy, 13*, 100627. PMID: 39296493

* **Collaborative Research – Large-Scale Observational Database: NCDB, SEER, and Others.**

1. Hall, W. A., Colbert, L. E., **Liu, Y.** ✪, Gillespie, T., Lipscomb, J., Hardy, C., … Landry, J. C. (**2013**). The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Cancer, 119(12), 2350-2357. PMID: 23625519
2. Kooby, D. A., Gillespie, T. W., **Liu, Y.** ✪, Byrd-Sellers, J., Landry, J., Bian, J., & Lipscomb, J. (**2013**). Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. *Ann Surg Oncol, 20*(11), 3634-3642. PMID: 23771249
3. Hall, W. A., Colbert, L. E., Nickleach, D., Switchenko, J., **Liu, Y.** ✩, Gillespie, T., . . . Landry, J. C. (**2014**). The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. *J Gastrointest Oncol, 5*(2), 77-85. PMID: 24772334
4. Colbert, L. E., Hall, W. A., Nickleach, D., Switchenko, J., Kooby, D. A., **Liu, Y.** ✩, . . . Landry, J. C. (**2014**). Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. *Cancer, 120*(4), 499-506. PMID: 24390739
5. Mikell, J. L., Gillespie, T. W., Hall, W. A., Nickleach, D. C., **Liu, Y.** ✩, Lipscomb, J., . . . Higgins, K. A. (**2015**). Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base. *J Thorac Oncol, 10*(3), 462-471. PMID: 25384064
6. Khullar, O. V., Gillespie, T., Nickleach, D. C., **Liu, Y.** ✩, Higgins, K., Ramalingam, S., . . . Fernandez, F. G. (**2015**). Socioeconomic risk factors for long-term mortality after pulmonary resection for lung cancer: an analysis of more than 90,000 patients from the National Cancer Data Base. *J Am Coll Surg, 220*(2), 156-168.e154.PMID: 25488349
7. Nanda, R. H.**\***, **Liu, Y.** ✩, Gillespie, T. W., Mikell, J. L., Ramalingam, S. S., Fernandez, F. G., . . . Higgins, K. A. (**2015**). Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis. *Cancer, 121*(23), 4222-4230. PMID: 26348268

##### Melvan, J. N., Sancheti, M. S., Gillespie, T., Nickleach, D. C., Liu, Y. ✩, Higgins, K., . . . Fernandez, F. G . (2015). Nonclinical Factors Associated with 30-Day Mortality after Lung Cancer Resection: An Analysis of 215,000 Patients Using the National Cancer Data Base. J Am Coll Surg, 221(2), 550-563. PMID: 26206651

1. Khullar, O. V., **Liu, Y.** ✪*,* Gillespie, T., Higgins, K. A., Ramalingam, S., Lipscomb, J., & Fernandez, F. G. (**2015**). Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data Base. *J Thorac Oncol, 10*(11), 1625-1633. PMID: 26352534
2. Medbery, R. L., Gillespie, T. W., **Liu, Y.** ✪, Nickleach, D. C., Lipscomb, J., Sancheti, M. S., . . . Fernandez, F. G . (**2016**). Nodal Upstaging Is More Common with Thoracotomy than with VATS During Lobectomy for Early-Stage Lung Cancer: An Analysis from the National Cancer Data Base. *J Thorac Oncol, 11*(2), 222-233. PMID: 26792589
3. Medbery, R. L., Gillespie, T. W., **Liu, Y.** ✪, Nickleach, D. C., Lipscomb, J., Sancheti, M. S., . . . Fernandez, F. G. (**2016**). Socioeconomic Factors Are Associated with Readmission After Lobectomy for Early Stage Lung Cancer. *Ann Thorac Surg, 102*(5), 1660-1667. PMID: 27476821
4. Jegadeesh, N., **Liu, Y.** ✩, Gillespie, T., Fernandez, F., Ramalingam, S., Mikell, J., . . . Higgins, K. A. (**2016**). Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National Cancer Data Base. *Clin Lung Cancer, 17*(5), 398-405. PMID: 26936682
5. Zureikat, A. H., Postlewait, L. M., **Liu, Y.** ✪, Gillespie, T. W., Weber, S. M., Abbott, D. E., . . . Kooby, D. A. (**2016**). A Multi-institutional Comparison of Perioperative Outcomes of Robotic and Open Pancreaticoduodenectomy. *Ann Surg, 264*(4), 640-649. PMID: 27433907
6. Higgins, K. A., O'Connell, K. **\***, **Liu, Y.** ✩, Gillespie, T. W., McDonald, M. W., Pillai, R. N., . . . Simone II, C. B. (**2017**). National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys, 97(1), 128-137. PMID: 27979443
7. Jegadeesh, N., **Liu, Y.** ✪, Zhang, C., Zhong, J., Cassidy, R. J., Gillespie, T., Kucuk, O., . . . Jani, A. B. (**2017**). The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer. *Cancer, 123*(3), 512-520. PMID: 27859018
8. Cassidy, R. J., **Liu, Y.** ✪, Patel, K., Zhong, J., Steuer, C. E., Kooby, D. A., . . . Landry, J. C. (**2017**). Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base. *Cancer, 123*(5), 783-793. PMID: 27780316
9. Cassidy, R. J., **Liu, Y.** ✩, Kahn, S. T., Jegadeesh, N. K., Liu, X.**\***, Subhedar, P. D., . . . Torres, M. A. (**2017**). The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer. *Cancer, 123*(15), 2829-2839. PMID:28387923
10. Ahmed, H. Z., **\*** **Liu, Y.** ✩, O'Connell, K. **\***,Ahmed, M. Z., Cassidy, R. J., Gillespie, T. W., . . . Higgins, K. A. (**2017**). Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis. *Clin Lung Cancer, 18*(6), 706-718. PMID: 28601387
11. Gerhard, R. S., Patil, D., **Liu, Y.** ✩, Ogan, K., Alemozaffar, M., Jani, A. B., . . . Filson, C. P. (**2017**). Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology. Urol Oncol, 35(5), 250-256. PMID: 28089387
12. Steuer, C. E., Behera, M., **Liu, Y.** ✩, Fu, C. **\***, Gillespie, T. W., Saba, N. F., . . . Ramalingam, S. S. (**2017**). Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. *Clin Lung Cancer, 18*(3), 286-292. PMID: 28043773
13. Naik, K. B.**\***, **Liu, Y.** ✩, Goodman, M., Gillespie, T. W., Pickens, A., orce, S. D., . . . Saba, N. F. (**2017**). Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. *Cancer, 123*(18), 3476-3485. PMID:28464264
14. Evans, M., **Liu, Y.** ✩, Chen, C.**\***, Steuer, C., Cassidy, R., III, Landry, J., . . . Saba, N. F. (**2017**). Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. *Oncology, 93*(5), 336-342. PMID:28848104
15. Jhaveri, J., Rayfield, L.**\***, **Liu, Y.** ✩, Chowdhary, M., Cassidy, R. J., Madden, N. A., . . . Landry, J. C. (**2017**). Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base. *J Gastrointest Oncol, 8*(6), 998-1008. PMID: 29299360
16. Jhaveri, J., **Liu, Y.** ✪, Chowdhary, M., Buchwald, Z. S., Gillespie, T. W., Olson, J. J., . . . Curran, W. J. (**2018**). Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high-risk grade 2 glioma: An analysis of the National Cancer Data Base. Cancer, 124(6), 1169-1178. PMID:29205287
17. Becerra-Culqui, T. A., **Liu, Y**. ✪, Nash, R., Cromwell, L., Flanders, W. D., Getahun, D., . . . Goodman, M. (**2018**). Mental Health of Transgender and Gender Nonconforming Youth Compared with Their Peers. *Pediatrics, 141*(5). PMID: 29661941
18. Jiang, R., **Liu, Y.** ✩, Ward, K. C., Force, S. D., Pickens, A., Sancheti, M. S., . . . Khullar, O. V. (**2018**). Excess Cost and Predictive Factors of Esophagectomy Complications in the SEER-Medicare Database. *Ann Thorac Surg, 106*(5), 1484-1491. PMID:2994881
19. Johnson, A. C., Ethun, C. G., **Liu, Y.** ✪, Lopez-Aguiar, A. G., Tran, T. B., Poultsides, G., . . . Maithel, S. K. (**2018**). Studying a Rare Disease Using Multi-Institutional Research Collaborations vs Big Data: Where Lies the Truth? *J Am Coll Surg, 227*(3), 357-366. PMID:29906615
20. Li, S., Wang, J., Zhang, B., **Liu, Y.**, Lu, T., Shi, Y., . . . Dong, L. (**2018**). Urinary Lead Concentration Is an Independent Predictor of Cancer Mortality in the U.S. General Population. *Front Oncol, 8*, 242. PMID:30013948
21. Ferris, M. J., **Liu, Y.** ✩, Ao, J., **\*** Zhong, J., Abugideiri, M., Gillespie, T. W., . . . Jani, A. B. (**2018**). The addition of chemotherapy in the definitive management of high risk prostate cancer. *Urol Oncol, 36*(11), 475-487. PMID: 30309766
22. Jhaveri, J., Rayfield, L.**\***, **Liu, Y.** ✩, Chowdhary, M., Tian, S., Cassidy, R. J., . . . Patel, K. R. (**2018**). Impact of intensity modulated radiation therapy on survival in anal cancer. *J Gastrointest Oncol, 9*(4), 618-630. PMID:30151258
23. Johnson, A. C., Ethun, C. G., **Liu, Y.** ✪, Poultsides, G., Howard, J. H., Bedi, M., . . . Cardona, K. (**2018**). A novel, simplified, externally validated staging system for truncal/extremity soft tissue sarcomas: An analysis of the US Sarcoma Collaborative database. *J Surg Oncol, 118*(7), 1135-1141. PMID: 30261111
24. Jhaveri, J., Cheng, E.**\***,Tian, S., Buchwald, Z., Chowdhary, M., **Liu, Y.** ✩, . . . Patel, K. R. (**2018**). Proton vs. Photon Radiation Therapy for Primary Gliomas: An Analysis of the National Cancer Data Base. *Front Oncol, 8*, 440. PMID: 30547008
25. Jia, Z., Li, X., Yuan, X., Zhang, B., **Liu, Y**. ✩, Zhao, J., & Li, S. (**2019**). Depression is associated with diabetes status of family members: NHANES (1999-2016). *J Affect Discord*. PMID: 30771642.
26. Gupta, D. R., **Liu, Y.**✪, Jiang, R., Walid, S., Higgins, K., Landry, J., . . . Saba, N. F. (**2019**). Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis. *Oncology*, 1-9. PMID: 31108497.
27. Troeschel, A. N.**\***, **Liu, Y.** ✩, Collin, L. J., Bradshaw, P. T., Ward, K. C., Gogineni, K., & McCullough, L. E. (**2019**). Race differences in cardiovascular disease and breast cancer mortality among US women diagnosed with invasive breast cancer. *Int J Epidemiol*. doi:10.1093/ije/dyz108. PMID: 31155644.
28. Zaidi, M. Y., Ethun, C. G., **Liu, Y.** ✪, Poultsides, G., Howard, J. H., Mogal, H., . . . Cardona, K. (**2019**). The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multi-institutional propensity score analysis from the US Sarcoma Collaborative. *J Surg Oncol*. PMID: 31172536.
29. Arciero, C., **Liu, Y.** ✪, Gillespie, T., & Subhedar, P. (**2019**). Surgery and survival in patients with stage IV breast cancer. Breast J. doi:10.1111/tbj.13296. PMID: 31087448.
30. Li, S., Wang, J., Zhang, B., Li, X., **Liu, Y.** ✩ (**2019**). Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study. *Diabetes Metab J, 43*(3): 319-341. PMID: 31210036.
31. Koerner, C., Sheng, X.**\***, **Liu, Y.** ✪, Gillespie, T., Balch, G., Shaffer, V.,… Sullivan, P. (**2019**). Decreased Overall Survival of Transanal vs. Transabdominal Resection of Early Rectal Cancer in Treatment Naïve Patients: A National Cancer Data Base Study. *Journal of Surgery*. Vol. 7, No. 3, 2019, pp. 78-86.
32. Lee, R.M., **Liu, Y.** ✪, Gamboa, A.C., Zaidi, M.Y., Kooby, D.A., Shah, M.M., Cardona, K., Russell, M.C., Maithel, S.K. (**2019**). [Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: What is driving disparities in receipt of treatment?.](https://www.ncbi.nlm.nih.gov/pubmed/31301148/) *J Surg Oncol*. *120*(4), 611-623. doi:10.1002/jso.25632. PMID: 31301148
33. Shah, N. N., Xi, Y. **\***, **Liu, Y.** ✩, Koff, J. L., Flowers, C. R., Behera, M., & Cohen, J. B. (**2019**). Racial and Socioeconomic Disparities in Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2019.03.006. PMID: 31029647.
34. Gamboa, A. C., **Liu, Y.** ✪, Lee, R. M., Zaidi, M. Y., Staley, C. A., Russell, M. C., . . . Maithel, S. K. (**2019**). A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique. *J Surg Oncol, 120*(6), 932-939. doi:10.1002/jso.25679. [PMID: 31448820](http://discovere.emory.edu/openurl/01emory/01EMORY_services_page?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&__char_set=utf8&rft_id=info:pmid/31448820&rfr_id=info:sid/LibX&rft.genre=article).
35. Gamboa, A. C., **Liu, Y.** ✪, Lee, R. M., Zaidi, M. Y., Staley, C. A., Kooby, D. A., . . . Maithel, S. K. (**2019**). Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel? J Surg Oncol, 120(8), 1293-1301. doi:10.1002/jso.25731. PMID: 31621090
36. Bean, M. B., **Liu, Y.** ✪, Jiang, R., Steuer, C. E., Patel, M., McDonald, M. W., . . . Saba, N. F. (**2019**). Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) Data. Oncologist. [PMID: 31391295](http://discovere.emory.edu/openurl/01emory/01EMORY_services_page?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&__char_set=utf8&rft_id=info:pmid/31391295&rfr_id=info:sid/LibX&rft.genre=article).
37. Lee, R. M., **Liu, Y.** ✪, Gamboa, A. C., Staley, C. A., Kooby, D., Russell, M. C., . . . Maithel, S. K. (**2020**). Differences in outcome for patients with cholangiocarcinoma: Racial/ethnic disparity or socioeconomic factors? *Surgical Oncology, 34*, 126-133. PMID:32891317
38. Enofe, N., Morris, A. D., **Liu, Y.** ✪, Liang, W. **\***, Wu, C. S., Sullivan, P. S., . . . Shaffer, V. O. (**2020**). Receipt of Adjuvant Chemotherapy in Stage II Colon Cancer and Overall Survival: A National Cancer Database Study*. J Surg Res*, 252, 69-79. doi:10.1016/j.jss.2020.02.016. PMID: 32244127.
39. Behera, M., Steuer, C. E., **Liu, Y.** ✪, Fernandez, F., Fu, C. **\***, Higgins, K. A., . . . Ramalingam, S. S. (**2020**). Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis. *Oncologist*. doi:10.1634/theoncologist.2019-0661. PMID: 31943520
40. Patel, S. A., Goyal, S., **Liu, Y.** ✩, Moghanaki, D., Patel, P. R., Hanasoge, S., . . . Fischer-Valuck, B. W. (**2020**). Analysis of Radiation Facility Volume and Survival in Men With Lymph Node-Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy. JAMA Netw Open, 3(12), e2025143. doi:10.1001/jamanetworkopen.2020.25143. PMID: 33301015
41. Fischer-Valuck, B. W., Rao, Y. J., Brenneman, R. J., Patel, P. R., Filson, **Liu, Y**., C. P., Jani, A. B., . . . Patel, S. A. (2020). Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer. *Brachytherapy*, 19(5), 557-566. PMID: 32624405
42. Arciero, C. A., Diehl, A. H., 3rd, **Liu, Y**. ✪, Sun, Q. **\***, Gillespie, T., Li, X., & Subhedar, P. (**2020**). Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers*. J Surg Oncol*. PMID: 32668059
43. Royce, T. J., **Liu, Y.** ✪, Milowsky, M. I., Efstathiou, J. A., Jani, A. B., Fischer-Valuck, B., & Patel, S. A. (**2021**). Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. doi:10.1016/j.clgc.2021.03.007. PMID:33839040
44. Xu, K. M., **Liu, Y.** ✪, Gillespie, T. W., Osunkoya, A. O., Carthon, B., Bilen, M. A., . . . Jani, A. B. (**2021**). Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database. Clin Genitourin Cancer. doi:10.1016/j.clgc.2021.01.002. PMID: 33582100
45. Janopaul-Naylor, J. R., Zhong, J., **Liu, Y.** ✪, Zhang, C., Osunkoya, A. O., Joshi, S. S., . . . Jani, A. B. (**2021**). Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database. Clin Transl Radiat Oncol, 26, 30-34. doi:10.1016/j.ctro.2020.11.002. PMID: 33294644
46. Schlafstein, A., **Liu, Y.** ✩, Goyal, S., Kahn, S., Godette, K., Lin, J., . . . Patel, S. A. (**2021**). Regional Nodal Irradiation for Clinically Node-Positive Breast Cancer Patients with Pathologic Negative Nodes after Neoadjuvant Chemotherapy. Clin Breast Cancer. doi:<https://doi.org/10.1016/j.clbc.2021.06.003>. PMID: 34229943
47. McCall, N. S., **Liu, Y.** ✪, Patel, S. A., Hershatter, B., Moghanaki, D., Godette, K. D., . . . Jani, A. B. (**2021**). Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients With Localized, High-Risk Prostate Cancer. *Adv Radiat Oncol, 6*(6), 100803. doi:10.1016/j.adro.2021.100803. PMID: 34703954
48. Danko, D., **Liu, Y.** ✩, Geng, F. **\***, & Gillespie, T. W. (**2022**). Influencers of Immediate Postmastectomy Reconstruction: A National Cancer Database Analysis. *Aesthet Surg J, 42*(5), Np297-np311. doi:10.1093/asj/sjab415. PMID: 34864860
49. Fischer-Valuck, B. W., Baumann, B. C., Brown, S. A., Filson, C. P., Weiss, A., Mueller, R., **Liu, Y**. ✪, . . . Patel, S. A. (**2022**). Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer. *Eur Urol Open Sci, 37*, 80-89. doi:10.1016/j.euros.2021.12.011. PMID: 35243392
50. Patel, S. A., **Liu, Y**. ✪, Mahal, B. A., Jani, A. B., Sanda, M. G., Royce, T. J., & Fischer-Valuck, B. W. (**2022**). Association of race with receipt of definitive therapy for high risk prostate cancer in older men. *J Geriatr Oncol, 13*(2), 200-206. doi:10.1016/j.jgo.2021.09.012. PMID: 34563484
51. Stokes, W. A., Xiong, N. **\***, **Liu, Y**. ✩, Higgins, K. A., Tian, S., Bradley, J. D., . . . Rusthoven, C. G. (**2022**). Association of Operability With Post-Treatment Mortality in Early-Stage Non-Small Cell Lung Cancer. *Clin Lung Cancer, 23*(3), e231-e237. doi:10.1016/j.cllc.2021.12.012. PMID: 35093293
52. Syed, Y. A., Stokes, W., Rupji, M., **Liu, Y**. ✩, Khullar, O., Sebastian, N., . . . Moghanaki, D. (**2022**). Surgical Outcomes for Early Stage Non-small Cell Lung Cancer at Facilities With Stereotactic Body Radiation Therapy Programs. *Chest, 161*(3), 833-844. doi:10.1016/j.chest.2021.11.004. PMID: 34785235
53. Vijayvargiya, P., Trivedi, S., Rupji, M., Song, H. **\***, **Liu, Y**. ✩, Jiang, R., . . . Saba, N. F. (**2022**). Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas. *Oncologist, 27*(1), 48-56. doi:10.1093/oncolo/oyab001. PMID: 35305095
54. Patel, S. A., **Liu, Y. ✪**, Solanki, A. A., Baumann, B. C., Efstathiou, J. A., Jani, A. B., . . . Royce, T. J. (**2023**). Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer. *Urol Oncol*. PMID: 36725382.
55. Sebastian, N., Goyal, S., **Liu, Y.** ✩, Janopaul-Naylor, J. R., Patel, P. R., Dhere, V. R., . . . Patel, S. A. (**2023**). Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy. *JAMA Netw Open, 6*(8), e2327637. [Aug 2023; PMID: 37552479]
56. Schwieger, L., Postlewait, L. M., Subhedar, P. D., Geng, F. **\***, **Liu, Y.** ✩, Gillespie, T., & Arciero, C. A. (**2024**). Patterns of completion axillary dissection for patients with cT1-2N0 breast cancer undergoing total mastectomy with positive sentinel lymph nodes. *J Surg Oncol, 129*(3), 468-480. [Mar 2024; PMID: 37955191]
57. Janopaul-Naylor, J., **Liu, Y.** ✪, Cao, Y., Schlafstein, A. J., Steuer, C., Patel, M. R., . . . Stokes, W. A. (**2024**). Institution-level Patterns of Care for Early-stage Oropharynx Cancers in the United States. *Am J Clin Oncol*. [Jun 2024; PMID: 38898571]

* **Collaborative Research: Basic Science, Clinical Trial, Public Health, et al.**

1. Wagner, S. E., Burch, J. B., Hussey, J., Temples, T., Bolick-Aldrich, S., Mosley-Broughton, C., **Liu, Y**., . . . Hebert, J. R.. (**2009**). Soil zinc content, groundwater usage, and prostate cancer incidence in South Carolina. *Cancer Causes Control, 20*(3), 345-353.
2. Aelion, C. M., Davis, H. T., **Liu, Y**. ✪, Lawson, A. B., & McDermott, S. (**2009**). Validation of Bayesian kriging of arsenic, chromium, lead, and mercury surface soil concentrations based on internode sampling. *Environ Sci Technol, 43*(12), 4432-4438.
3. Wu, G. J., Wu, M. W., Wang, C., & **Liu, Y.** ✩ (**2011**). Enforced expression of METCAM/MUC18 increases tumorigenesis of human prostate cancer LNCaP cells in nude mice. *J Urol, 185*(4), 1504-1512.
4. Tan, C., de Noronha, R. G., Devi, N. S., Jabbar, A. A., Kaluz, S., **Liu, Y**. ✩, . . . Van Meir, E. G. (**2011**). Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. *Bioorg Med Chem Lett, 21*(18), 5528-5532.
5. Thaiparambil, J. T., Bender, L., Ganesh, T., Kline, E., Patel, P., **Liu, Y**. ✩, . . . Garcia, A. (**2011**). Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. *Int J Cancer, 129*(11), 2744-2755.
6. Mooring, S. R., Jin, H., Devi, N. S., Jabbar, A. A., Kaluz, S., **Liu, Y**. ✩, . . . Wang, B. (**2011**). Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. *J Med Chem, 54*(24), 8471-8489.
7. Qureshi, A. I., Palesch, Y. Y., Martin, R., Novitzke, J., Cruz-Flores, S., Ehtisham, A., . . . **Liu, Y**. ✩ (**2011**). Association of serum glucose concentrations during acute hospitalization with hematoma expansion, perihematomal edema, and three month outcome among patients with intracerebral hemorrhage. *Neurocrit Care, 15*(3), 428-435.
8. Zeng, G., Cai, S., **Liu, Y.** ✩, & Wu, G. J. (**2012**). METCAM/MUC18 augments migration, invasion, and tumorigenicity of human breast cancer SK-BR-3 cells. *Gene, 492*(1), 229-238.
9. Mun, J., Jabbar, A. A., Devi, N. S., **Liu, Y.** ✩, Van Meir, E. G., & Goodman, M. M. (**2012**). Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide , a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent. *Bioorg Med Chem, 20*(14), 4590-4597.
10. Pentz, R. D., White, M., Harvey, R. D., Farmer, Z. L., **Liu, Y**. ✩, Lewis, . . . Khuri, F. R. (**2012**). Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. *Cancer, 118*(18), 4571-4578.
11. Zelnak, A. B., Styblo, T. M., Rizzo, M., Gabram, S. G., Wood, W. C., Harichand-Herdt, S., . . . O'Regan, R. M. (**2013**). Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers. *Clin Breast Cancer, 13*(3), 173-179.
12. Hagen, K. R., Zeng, X., Lee, M. Y., Tucker Kahn, S., Harrison Pitner, M. K., Zaky, S. S., . . . Saavedra, H. I. (**2013**). Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. *Cell Div, 8*(1), 10.
13. Patel, K., Wen, J., Magliocca, K., Muller, S., **Liu, Y.** ✩, Chen, Z. G., . . . Diaz, R. (**2014**). Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. *Cancer Chemother Pharmacol, 74*(5), 1015-1022.
14. Braxton, D. R., Nickleach, D. C., **Liu, Y.** ✩, & Farris, A. B., 3rd. (**2014**). Necrotizing sialometaplasia-like change of the esophageal submucosal glands is associated with Barrett's esophagus. *Virchows Arch, 465*(2), 135-143.
15. Pentz, R. D., Hendershot, K. A., Wall, L., White, T. E., Peterson, S. K., Thomas, C. B., **Liu, Y**., . . . Khuri, F.R. (**2015**). Development and testing of a tool to assess patient preferences for phase I clinical trial participation. *Psychooncology, 24*(7), 835-838.
16. Morreall, J., Kim, A., **Liu, Y.** ✩, Degtyareva, N., Weiss, B., & Doetsch, P. W. (**2015**). Evidence for Retromutagenesis as a Mechanism for Adaptive Mutation in Escherichia coli. *PLoS Genet, 11*(8), e1005477.
17. Anisuzzaman, A. S., Haque, A., Rahman, M. A., Wang, D., Fuchs, J. R., Hurwitz, S., **Liu, Y**., . . . Amin, A. (**2016**). Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers. *Cancer Prev Res (Phila), 9*(1), 63-73.
18. Wang, D., Peng, S., Amin, A. R., Rahman, M. A., Nannapaneni, S., **Liu, Y.**, . . . Chen, Z. G. (**2016**). Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-Phenanthroline. *PLoS One, 11*(12), e0168450.
19. Feng, D.\*, Zhang, D., Li, B., Zhang, Y., Serrano, R., Shi, D., **Liu, Y**. ✩, . . . Zhang, L. (**2017**). Does having a usual primary care provider reduce patient self-referrals in rural China's rural multi-tiered medical system? A retrospective study in Qianjiang District, China. *BMC Health Serv Res, 17*(1), 778. PMID:29179717
20. Liu, F., **Liu, Y.** ✪, Liu, X., Mao, K., Zhong, D., Marcus, A. I., . . . Zhou, W. (**2018**). Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. *Lung Cancer, 123*, 36-43. PMID:30089593
21. Paplomata, E., Zelnak, A., Santa-Maria, C.A., **Liu, Y.** ✪, Gogineni, K.… O'Regan, R.M. (**2019**). [Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/30745109) *Clin Breast Cancer, 19*(3), 188-196. doi:10.1016/j.clbc.2018.12.017. PMID: 30745109.
22. White, B. N., Okoli, J., Dixon, J. B., **Yuan, L**. ✪, Yang, S., & Gabram-Mendola, S. G. A. (**2021**). Use of a portable infrared 3D scanning device measuring limb volume in a safety net hospital breast clinic. Breast J. doi:10.1111/tbj.14221. PMID: 33724606.
23. Liu, F., **Liu, Y.** ✪, Liu, X., Mao, K., Zhong, D., Marcus, A. I., . . . Zhou, W. (**2021**). Corrigendum to "Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer" [Lung Cancer 123 (2018) 36-43]. Lung Cancer, 154, 227. doi:10.1016/j.lungcan.2021.02.012. PMID:33612293.
24. Jin, R., Liu, B., Liu, X., Fan, Y., Peng, W., Huang, C., . . . **Liu, Y.** ✪, Zhou, W. (**2021**). Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis. Mol Cancer Ther, 20(2), 274-283. doi:10.1158/1535-7163.Mct-20-0567. PMID:33293343.
25. Carlisle, J. W., Jansen, C. S., Cardenas, M. A., Sobierajska, E., Reyes, A. M., Greenwald, R., . . . **Liu, Y.**, Kissick, H. (2022). Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. *J Immunother Cancer, 10*(7). doi:10.1136/jitc-2022-004803. PMID: 35863822
26. Osta, B. E., Carlisle, J., Steuer, C., Pakkala, S., Leal, T., Dhodapkar, M., **Liu, Y**. ✪, . . . Ramalingam, S. (2022). A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. *Clin Lung Cancer*. doi:10.1016/j.cllc.2022.06.003. PMID: 35863963
27. Ruggieri, A. N., Yarchoan, M., Goyal, S., **Liu, Y.** ✩, Sharon, E., Chen, H. X., . . . Lesinski, G. B. (2022). Combined MEK/PD-L1 inhibition alters peripheral cytokines and lymphocyte populations correlating with improved clinical outcomes in advanced biliary tract cancer. *Clin Cancer Res*. doi:10.1158/1078-0432.Ccr-22-1123. PMID: 35833954
28. Veitinger, J. K., Kerber, A. S., Gabram-Mendola, S. G. A., **Liu, Y.** ✩, Durham, L. M., Durrence, D., . . . Guan, Y. (2022). Screening for Individuals at Risk for Hereditary Breast and Ovarian Cancer: A Statewide Initiative, Georgia, 2012-2020. *Am J Public Health*, e1-e4. doi:10.2105/ajph.2022.306932. PMID: 35862880
29. Davis-Gardner, M. E., Lai, L., Wali, B., Samaha, H., Solis, D., Lee, M., . . . Suthar, M. S. (**2023**). Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. *N Engl J Med, 388*(2), 183-185. PMID: 36546661
30. Osta, B. E., Carlisle, J., Steuer, C., Pakkala, S., Leal, T., Dhodapkar, M., . . . Ramalingam, S. (**2022**). A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. *Clin Lung Cancer, 23*(7), e400-e404. PMID: 35863963
31. Ravindranathan, S., Passang, T., Li, J. M., Wang, S., Dhamsania, R., Ware, M. B., . . . Waller, E. K. (**2022**). Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. *Nature communications, 13*(1), 6418. PMID: 36302761
32. Saba, N. F., Steuer, C. E., Ekpenyong, A., McCook-Veal, A., **Liu, Y.** ✩, Magliocca, K., Patel, M., . . . Chung, C. H. (**2023**). Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. *Nat Med, 29*(4), 880-887. PMID: 37012550
33. Shaib, W. L., Manali, R., **Liu, Y.** ✩, El-Rayes, B., Loehrer, P., O'Neil, B., . . . Bekaii-Saab, T. (**2023**). Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). *Eur J Cancer*. PMID: 37268519

* **Collaborative Research: Clinical Observational Studies for Association and Prediction.**

1. Shelton, J., Rossi, P. J., Chen, H., **Liu, Y.** ✪, Master, V. A., & Jani, A. B. (**2011**). Observations on prostate intrafraction motion and the effect of reduced treatment time using volumetric modulated arc therapy. *Pract Radiat Oncol, 1*(4), 243-250. PMID: 24674002
2. Oprea-Ilies, G., Haus, E., Sackett-Lundeen, L., **Liu, Y.** ✪, McLendon, L., Busch, R., . . . Cohen, C. (**2013**). Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival. *Breast Cancer Res Treat, 137*(3), 677-687. PMID: 23250547
3. Pillai, R. N., Brodie, S. A., Sica, G. L., Shaojin, Y., Li, G., Nickleach, D. C., **Liu, Y.**, . . . Brandes, J. C. (**2013**). CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. *Clin Cancer Res, 19*(6), 1603-1611. PMID: 23386692
4. Eaton, B. R., Kim, H. S., Schreibmann, E., Schuster, D. M., Galt, J. R., Barron, B., . . . Fox, T. (**2014**). Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma. *J Vasc Interv Radiol, 25*(2), 288-295. PMID: 24269792
5. Colbert, L. S., Wilson, K., Kim, S., **Liu, Y.** ✩, Oprea-Ilies, G., Gillespie, C., . . . Gonzalez-Perez, R. R. (**2014**). NILCO biomarkers in breast cancer from Chinese patients. *BMC Cancer, 14*, 249. PMID: 24716804
6. Shaffer, V. O., Baptiste, C. D., **Liu, Y**. ✪, Srinivasan, J. K., Galloway, J. R., Sullivan, P. S., . . . Gillespie, T. W. (**2014**). Improving quality of surgical care and outcomes: factors impacting surgical site infection after colorectal resection. *Am Surg, 80*(8), 759-763. PMID: 25105393
7. Revenig, L. M., Canter, D. J., Henderson, M. A., Ogan, K., Kooby, D. A., Maithel, S. K., . . . Master, V. A. (**2015**). Preoperative quantification of perceptions of surgical frailty. *J Surg Res, 193*(2), 583-589. PMID: 25266605
8. Zelnak, A. B., Nikolinakos, P., Srinivasiah, J., Jonas, W., Pippas, A., **Liu, Y**., . . . Georgia Ctr Oncology Res, E. (**2015**). High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy. *Clin Breast Cancer, 15*(1), 31-36. PMID: 25065563
9. Zhong, J., Ali, A. N., Voloschin, A. D., **Liu, Y.** ✪, Curran, W. J., Jr., Crocker, I. R., & Shu, H. K. (**2015**). Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. *Cancer, 121*(9), 1456-1462. PMID: 25557543
10. Jegadeesh, N., Rajpara, R., Esiashvili, N., Shi, Z., **Liu, Y.** ✪, Okwan-Duodu, D., . . . Khan, M. K. (**2015**). Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation. *Int J Radiat Oncol Biol Phys, 92*(1), 107-112. PMID: 25863758
11. Revenig, L. M., Canter, D. J., Kim, S., **Liu, Y.** ✩, Sweeney, J. F., Sarmiento, J. M., . . . Ogan, K. (**2015**). Report of a Simplified Frailty Score Predictive of Short-Term Postoperative Morbidity and Mortality. *J Am Coll Surg, 220*(5), 904-911.e901. PMID: 25907870
12. Jegadeesh, N., **Liu, Y.** ✪, Prabhu, R. S., Magliocca, K. R., Marcus, D. M., Higgins, K. A., . . . Beitler, J. J. (**2015**). Outcomes and prognostic factors in modern era management of major salivary gland cancer. *Oral Oncol, 51*(8), 770-777. PMID: 26033470
13. Press, R. H., Prabhu, R. S., Nickleach, D. C., **Liu, Y.** ✩, Shu, H. K., Kandula, S., . . . Crocker, I. (**2015**). Novel risk stratification score for predicting early distant brain failure and salvage whole-brain radiotherapy after stereotactic radiosurgery for brain metastases. *Cancer, 121*(21), 3836-3843. PMID: 26242475
14. McDonald, M. W., **Liu, Y.** ✪, Moore, M. G., & Johnstone, P. A. (**2016**). Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy. *Radiat Oncol, 11*, 32. PMID: 26922239
15. McDonald, M. W., Zolali-Meybodi, O., Lehnert, S. J., Estabrook, N. C., **Liu, Y.** ✪, Cohen-Gadol, A. A., & Moore, M. G. (**2016**). Reirradiation of Recurrent and Second Primary Head and Neck Cancer With Proton Therapy. *Int J Radiat Oncol Biol Phys, 96*(4), 808-819. PMID: 27788954
16. Krieger, D. A., Hudgins, P. A., Nayak, G. K., Baugnon, K. L., Corey, A. S., Patel, M. R., **Liu, Y.**, . . . Aiken, A. H. (**2017**). Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma. *AJNR Am J Neuroradiol, 38*(6), 1193-1199. PMID: 28364010
17. McCracken, D. J., Higginbotham, R. A., Boulter, J. H., **Liu, Y.** ✪, Wells, J. A., Halani, S. H., . . . Olson, J. J. (**2017**). Degree of Vascular Encasement in Sphenoid Wing Meningiomas Predicts Postoperative Ischemic Complications. *Neurosurgery, 80*(6), 957-966. PMID: 28327941
18. Harris, W. B., Zhang, C., **Liu, Y**. ✩, Robertson, D. K., Akbashev, M. Y., Lingerfelt, B. M., . . . Master, V. A. (**2017**). Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma. *Tumour Biol, 39*(6), 1010428317705514. PMID: 28327941
19. Makhani, S. S., Kim, F. Y., **Liu, Y.** ✩, Ye, Z.**\***, Li, J. L., Revenig, L. M., . . . Master, V. A. (**2017**). Cognitive Impairment and Overall Survival in Frail Surgical Patients. *J Am Coll Surg, 225*(5), 590-600.e591. PMID:28826805
20. Albers, L. N., **Liu, Y**. ✩, Bo, N.**\***, Swerlick, R. A., & Feldman, R. J. (**2017**). Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. *J Am Acad Dermatol, 77*(6), 1074-1082. PMID:28927663
21. Patel, K. R., Shoukat, S., Oliver, D. E., Chowdhary, M., Rizzo, M., Lawson, D. H., **Liu, Y**., . . . Khan, M. K. (**2017**). Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. *Am J Clin Oncol, 40*(5), 444-450. PMID:26017484
22. Thareja, S., Fink, M., Chen, K. H., **Liu, Y.** ✪, Chen, S. C., & Stoff, B. K. (**2018**). Race as a predictor of patient preferences for biopsy result communication. *J Am Acad Dermatol, 78*(6), 1223-1225.e1221. PMID:29223577
23. Meisel, J., Zhang, C., Neely, C., Mendoza, P., You, S., Han, T., **Liu, Y**., . . . Li, X. (**2018**). Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. *Clin Breast Cancer, 18*(5), 347-352. PMID:29305309
24. Steuer, C. E., Griffith, C. C., Nannapaneni, S., Patel, M. R., **Liu, Y.** ✪, Magliocca, K. R., . . . Saba, N. F (**2018**). A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. *Mol Cancer Ther, 17*(3), 710-716.PMID:29440293
25. Bilen, M. A., Dutcher, G. M. A., **Liu, Y**. ✪, Ravindranathan, D., Kissick, H. T., Carthon, B. C., . . . Master, V. A. (**2018**). Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. *Clin Genitourin Cancer, 16*(3), e563-e575. PMID:29402706
26. Szederjesi, A., Baronciani, L., Budde, U., Castaman, G., Lawrie, A. S., **Liu, Y.**, . . . Bodo, I. (**2018**). An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study. *J Thromb Haemost*, *16*, 1604-1613. PMID:29897666
27. Patel, M. R., Hudgins, P. A., Beitler, J. J., Magliocca, K. R., Griffith, C. C., **Liu, Y.,** . . . Aiken, A. H. (**2018**). Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer. *ORL J Otorhinolaryngol Relat Spec, 80*(2), 85-95. PMID:29969771
28. Kim, C. C., Berry, E. G., Marchetti, M. A., Swetter, S. M., Lim, G., Grossman, D., **Liu, Y.,** . . . Chen, S. C. (**2018**). Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. *JAMA Dermatol, 154*(12), 1401-1408. PMID:30304348
29. Bilen, M. A., Martini, D. J., **Liu, Y.** ✪, Lewis, C., Collins, H. H., Shabto, J. M., . . . Harvey, R. D. (**2018**). The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. *Cancer, 125*(1), 127-134. PMID:30329148
30. Martini, D.J., **Liu, Y.** ✪, Shabto, J.M., Lewis, C., Kline, M.R., … Bilen, M.A. (**2019**). [Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.](https://www.ncbi.nlm.nih.gov/pubmed/30725388) *Invest New Drugs*. PMID: 30725388.
31. Jia, Z., Li, X., Yuan, X., Zhang, B., **Liu, Y**.✩, Zhao, J., & Li, S. (**2019**). Depression is associated with diabetes status of family members: NHANES (1999-2016). *J Affect Disord, 249*, 121-126. PMID: 30771642.
32. Polansky, M., Eisenstadt, R., DeGrazia, T., Zhao, X. **\***, **Liu, Y.** ✩, & Feldman, R. (**2019**). Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients. *J Am Acad Dermatol*. doi:10.1016/j.jaad.2019.03.049. PMID: 30923002.
33. Bilen, M. A., Shabto, J. M., Martini, D. J., **Liu, Y.** ✪, Lewis, C., Collins, H., . . . Harvey, R. D. (**2019).** Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. *BMC Cancer*, 19(1), 857.  [PMID: 31464611](http://discovere.emory.edu/openurl/01emory/01EMORY_services_page?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&__char_set=utf8&rft_id=info:pmid/31464611&rfr_id=info:sid/LibX&rft.genre=article)
34. Yusuf, M. A., Mahmoud, N. D., Rirash, F. R., Stoff, B. K., **Liu, Y.** ✪, & McMichael, J. R. (**2019**). Skin lightening practices, beliefs, and self-reported adverse effects among female health science students in Borama, Somaliland: A cross- sectional survey. *Int J Womens Dermatol, 5*(5), 349-355. doi:10.1016/j.ijwd.2019.08.006. PMID: 31909156
35. Rosenblum, J. M., Binongo, J., Wei, J., **Liu, Y.** ✩, Leshnower, B. G., Chen, E. P., . . . Keeling, W. B. (**2019**). Priorities in coronary artery bypass grafting: Is midterm survival more dependent on completeness of revascularization or multiple arterial grafts? *J Thorac Cardiovasc Surg*. doi:10.1016/j.jtcvs.2019.11.125. PMID:32005574
36. Holbrook, A. I., Zhang, J., D’amico, K., **Liu, Y.** ✪**,** & Newell, M. S. (**2019**). The Association of Breast Pain with Malignancy. *Journal of Breast Imaging, 1*(3), 177-181.
37. Arciero, C., Buhariwalla, K., **Liu, Y.** ✪, Torres, M. A., & Subhedar, P. (**2020**). Time from Completion of Neo-adjuvant Chemotherapy to Surgery: Effects on Outcomes in Breast Cancer Patients. *Breast J*, 26(2), 155-161. doi:10.1111/tbj.13482. PMID: 31448512
38. Jansen, C. S., Prokhnevska, N., Master, V. A., Sanda, M. G., Carlisle, J. W., Bilen, M. A., . . . **Liu, Y.** ✩, Kissick, H. (**2019**). An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. *Nature, 576*(7787), 465-470. doi:10.1038/s41586-019-1836-5. PMID:31827286
39. Hall, K. H., **Liu, Y.** ✩**,** Jiang, C. **\***, & Harvey, R. D. (**2020**). New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer. *Pharmacotherapy*, 40(2), 133-141. doi:10.1002/phar.2354. PMID: 31863604
40. Martini, D. J., **Liu, Y.** ✪, Master, V. A., Harvey, R. D., & Bilen, M. A. (**2020**). Reply to body fat indices and survival in immunotherapy-treated patients with cancer. *Cancer*. doi:10.1002/cncr.32886. PMID:32286681
41. Martini, D. J., **Liu, Y.** ✪, Shabto, J. M., Carthon, B. C., Hitron, E. E., Russler, G. A., . . . Bilen, M. A. (**2020**). Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. *Oncologist*, 25(3), e484-e491. doi:10.1634/theoncologist.2019-0578. PMID: 32162798
42. Martini, D. J., Kline, M. R., **Liu, Y.** ✪, Shabto, J. M., Williams, M. A., Khan, A. I., . . . Bilen, M. A. (**2020**). Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer, 126(3), 575-582. doi:10.1002/cncr.32576. PMID:31648379
43. Rolader, R., Daugherty, L. N., **Liu, Y.** ✪, & Feldman, R. J. (**2020**). Prevalence and predictors of pruritus in pemphigus compared with bullous pemphigoid: A cross-sectional study. *J Am Acad Dermatol*. doi:10.1016/j.jaad.2020.01.025. PMID:33286681.
44. Shabto, J. M., Martini, D. J., **Liu, Y.** ✪, Ravindranathan, D., Brown, J., Hitron, E. E., . . . Bilen, M. A. (**2020**). Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. *Cancer Med, 9*(8), 2752-2760. doi:10.1002/cam4.2932. PMID:32100417
45. Bilen, M. A., Martini, D. J., **Liu, Y.** ✪, Shabto, J. M., Brown, J. T., Williams, M., . . . Master, V. A. (**2020**). Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. *Oncologist, 25*(3), e528-e535. doi:10.1634/theoncologist.2019-0751. PMID: 32162807
46. Chen, Y. L., Zeng, M., **Liu, Y.**, Xu, Y., Bai, Y., Cao, L., . . . Yin, Y. (**2020**). CHA2DS2-VASc Score for Identifying Patients at High Risk of Postoperative Atrial Fibrillation After Cardiac Surgery: A Meta-analysis*. Ann Thorac Surg, 109*(4), 1210-1216. doi:10.1016/j.athoracsur.2019.07.084. PMID:31521590
47. Holbrook, A., Vey, B., Kim, Y. J., **Liu, Y.** ✪**,** & Newell, M. (**2020**). Utility of tomosynthesis in decreasing skin calcification workup rate. *American Journal of Diagnostic Imaging, 6*(1), 1-6.
48. Shin, D. M., Nannapaneni, S., Patel, M. R., Shi, Q., **Liu, Y.**, Chen, Z., . . . Saba, N. F. (**2020**). Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. Clin Cancer Res. PMID: 32943457
49. Nazha, B., Goyal, S., Chen, Z., Engelhart, A., Carlisle, J. W., Beardslee, T. J., . . . **Liu, Y.,** Owonikoko, T. K. (**2020**). Efficacy and safety of immune checkpoint blockade in self-identified black patients with advanced non-small cell lung cancer. Cancer. PMID: 32902858
50. Maliniak, M. L. **\***, Cheriyan, A. M., Sherman, M. E., **Liu, Y.** ✪, Gogineni, K., Liu, J., . . . McCullough, L. E. (**2020**). Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer. Breast Cancer Res, 22(1), 65. PMID: 32552729
51. Szederjesi, A., Baronciani, L., Budde, U., Castaman, G., Colpani, P., Lawrie, A. S., . . . **Liu, Y.** ✪**,** Bodó, I. (**2020**). Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers. J Thromb Haemost. PMID: 32573891
52. Collin, L. J. **\***, Troeschel, A. N., **Liu, Y.** ✪, Gogineni, K., Borger, K., Ward, K. C., & McCullough, L. E. (**2020**). A balancing act: racial disparities in cardiovascular disease mortality among women diagnosed with breast cancer. Ann Cancer Epidemiol, 4. PMID: 32954254
53. Brown, J. T., **Liu, Y.** ✪, Shabto, J. M., Martini, D. J., Ravindranathan, D., Hitron, E. E., . . . Bilen, M. A. (**2021**). Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist. doi:10.1002/onco.13727. PMID:33634507.
54. Akce, M., Liu, Y., Zakka, K., Martini, D. J., Draper, A., Alese, O. B., . . . El-Rayes, B. F. (**2021**). Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. Am J Clin Oncol, 44(2), 74-81. doi:10.1097/coc.0000000000000787. PMID: 33350681.
55. Smith, K. R., Brown, J. T., Wan, L. **\***, **Liu, Y**. ✩,Russler, G., Yantorni, L., . . . Bilen, M. A. (**2021**). Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. Oncologist. doi:10.1002/onco.13848. PMID:34096667
56. Martini, D. J., Kline, M. R., **Liu, Y.** ✪, Shabto, J. M., Carthon, B. C., Russler, G. A., . . . Bilen, M. A. (**2021**). Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer Treat Res Commun, 28, 100393. doi:10.1016/j.ctarc.2021.100393. PMID: 34029879
57. Martini, D. J., Goyal, S., **Liu, Y.** ✩, Evans, S. T., Olsen, T. A., Case, K., . . . Bilen, M. A. (**2021**). Immune-related adverse events as clinical biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors. Oncologist. doi:10.1002/onco.13868.PMID:34156726

Cole, E. F., DeGrazia, T., Sun, Y**\***, **Liu, Y**. ✩, & Feldman, R. J. (**2021**). Assessing Disease Outcome Measures in Bullous Pemphigoid on Standard-Of- Care Therapies. *JID Innov, 1*(4), 100050. PMID: 34909747

1. Dhere, V. R., Fischer-Valuck, B. W., Goyal, S., **Liu, Y**. ✩, Morgan, T. M., Ghavidel, E., . . . Patel, S. A. (**2021**). Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer. *Brachytherapy, 20*(6), 1130-1138. doi:10.1016/j.brachy.2021.07.005. PMID: 34417136
2. Martini, D. J., Shabto, J. M., Goyal, S., **Liu, Y**. ✩, Olsen, T. A., Evans, S. T., . . . Bilen, M. A. (**2021**). Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. *Oncologist, 26*(12), 1017-1025. doi:10.1002/onco.13922. PMID: 34342095
3. Smith, K. R., Brown, J. T., Wan, L. **\***, **Liu, Y**. ✩, Russler, G., Yantorni, L., . . . Bilen, M. A. (**2021**). Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. *Oncologist*. doi:10.1002/onco.13848. PMID: 34096667
4. Yarchoan, M., Cope, L., Ruggieri, A. N., Anders, R. A., Noonan, A. M., Goff, L. W., **Liu, Y.,** . . . Azad, N. S. (**2021**). Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. *J Clin Invest, 131*(24). doi:10.1172/jci152670. PMID: 34907910
5. Hadadi, A., Smith, K. E., Wan, L. **\***, Brown, J. R., Russler, G., Yantorni, L., . . . **Liu, Y**. ✩, Bilen, M. A. (**2022**). Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. *Urol Oncol, 40*(6), 271.e279-271.e218. doi:10.1016/j.urolonc.2022.03.016. PMID: 35466038
6. Webster, L. A., Newsome, J., Guo, M. **\***, Lee, S., Majdalany, B. S., Gichoya, J., **Liu, Y.,** . . . Kokabi, N. (**2022**). Utilization and Comparative Effectiveness of Uterine Artery Embolization versus Hysterectomy for Severe Postpartum Hemorrhage: A National Inpatient Sample Study. *J Vasc Interv Radiol, 33*(4), 427-435.e424. doi:10.1016/j.jvir.2021.12.004. PMID: 34915166
7. Martini, D. J., Evans, S. T., **Liu, Y**. ✩, Shabto, J. M., Uner, O. E., Olsen, T. A., . . . Bilen, M. A. (**2022**). Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. *Clin Genitourin Cancer, 20*(1), 53-59. doi:10.1016/j.clgc.2021.11.004. PMID: 34785235
8. Martini DJ, Olsen A, Goyal S, **Liu, Y**. ✩, Evans ST, Hitron E, Russler G, Yantorni L, Caulfield S, Brown JT, Goldman JM, Nazha B, Carthon BC, Harris WB, Kucuk O, Master VA, Bilen M. (**2022**). Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. *Journal of Immunotherapy and Precision Oncology*. 5(3): 52-57. PMID: 36034580
9. Bilen, M. A., Akintayo, A., **Liu, Y. ✪,** Abiodun-Ojo, O., Kucuk, O., Carthon, B. C., . . . Parent, E. E. (**2022**). Prognostic Evaluation of Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [(68)Ga]Ga DOTATATE PET-CT. *Cancers (Basel), 14*(24). PMID: 36551525
10. Zhuang, T. Z., Ravindranathan, D., **Liu, Y. ✪**, Martini, D. J., Brown, J. T., Nazha, B., . . . Bilen, M. A. (**2022**). Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. *Oncologist*. PMID: 36427017
11. Sanda, G. E., Shabto, J. M., Goyal, S., **Liu, Y.**✩, Martini, D. J., Nazha, B., . . . Bilen, M. A. (2023). Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors. *Oncologist*. PMID: 37285524
12. McDonald, M. W., Bates, J. E., McCall, N. S., Goyal, S., **Liu, Y.**✩, Rudra, S., . . . Swinney, E. (2023). Insurance Authorization and Access to Proton Therapy for Patients With Head and Neck Cancers. *Int J Radiat Oncol Biol Phys, 116*(2), 404-412. PMID: 36889515
13. Schmeusser, B. N., Manalo, T. A., **Liu, Y.**✩, Shah, Y. B., Ali, A., Armas-Phan, M., . . . Master, V. A. (2023). Mayo Adhesive Probability Score Does Not Have Prognostic Ability in Locally Advanced Renal Cell Carcinoma. *J Kidney Cancer VHL, 10*(1), 19-25. PMID: 36969300
14. Wells, J., Klosky, J. L., **Liu, Y. ✪**, & Gillespie, T. W. (2022). An overview of implementing an evidence based program to increase HPV vaccination in HIV community clinics. *BMC Public Health, 22*(1), 1696. PMID: 36071389
15. Carlisle, J., **Liu, Y.** ✪, & Leal, T. (**2024**). Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade. *J Clin Oncol*, Jco2400280. doi:10.1200/jco.24.00280. [Jun 2024; Epub ahead of print; PMID: 38833649]
16. Devin, C. L., Gillani, M., Shields, M. C., Eldredge, K., Kucera, W., Rupji, M., . . . **Liu, Y.** ✩, Rosen, S. A. (**2023**). Ratio of Economy of Motion: A New Objective Performance Indicator to Assign Consoles During Dual-Console Robotic Proctectomy. *Am Surg, 89*(8), 3416-3422. [Aug 2023; PMID: 36898676]
17. Gbolahan, O. B., Zhi, X., **Liu, Y.** ✩, Shah, M. M., Kooby, D. A., & Alese, O. B. (**2024**). Adjuvant Chemotherapy and Outcomes in Older Adult Patients With Biliary Tract Cancer. *JAMA Netw Open, 7*(1), e2351502. [Jan 2024; PMID: 38206623]
18. Gillani, M., Rupji, M., Devin, C., Purvis, L., Olson, T. P., Jarc, A., . . . **Liu, Y.** ✩, Rosen, S. (**2023**). Quantification of Surgical Workflow during Robotic Proctectomy. *Res Sq*. [Oct 2023; preprint; PMID: 37886442]
19. Janopaul-Naylor, J. R., Koo, A., Qian, D. C., McCall, N. S., **Liu, Y.** ✪, & Patel, S. A. (**2024**). Physician Assessment of ChatGPT and Bing Answers to American Cancer Society's Questions to Ask About Your Cancer. *Am J Clin Oncol, 47*(1), 17-21. [Jan 2024; PMID: 37823708]
20. Rosen, S. A., Rupji, M., **Liu, Y.** ✩, & Paul Olson, T. J. (**2023**). Robotic Proctectomy: Beyond the Initial Learning Curve. *Am Surg, 89*(12), 5332-5339. [Dec 2023; PMID: 36560892]
21. Sanda, G. E., Shabto, J. M., Goyal, S., **Liu, Y.** ✩, Martini, D. J., Nazha, B., . . . Bilen, M. A. (**2023**). Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors. *Oncologist*. [Dec 2023; PMID: 37285524]
22. Schwieger, L., Postlewait, L. M., Subhedar, P. D., Geng, F. **\***, **Liu, Y.** ✩, Gillespie, T., & Arciero, C. A. (**2024**). Patterns of completion axillary dissection for patients with cT1-2N0 breast cancer undergoing total mastectomy with positive sentinel lymph nodes. *J Surg Oncol, 129*(3), 468-480. [Mar 2024; PMID: 37955191]
23. Sun, L. F., Maples, K. T., Hall, K. H., **Liu, Y.** ✩, Cao, Y., Joseph, N. S., . . . Harvey, R. D. (**2023**). Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. *JCO Oncol Pract, 19*(9), 793-798. [July 2023; PMID: 37418682]
24. Saba, N. F., Wong, S. J., Nasti, T., McCook-Veal, A. A., McDonald, M. W., Stokes, W. A., . . . **Liu, Y.** ✩, Koyfman, S. A. (**2024**). Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial. *JAMA Oncol*. [May 2024; PMID: 38780927]
25. Passang, T., Wang, S., Zhang, H., Zeng, F., Hsu, P. C., Wang, W., . . . **Liu, Y.** ✩, Waller, E. K. (**2024**). VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer. *Cancer Res*. [May 2024; PMID: 38809694]
26. Nicaise, E. H., Palmateer, G., Schmeusser, B. N., Futral, C., **Liu, Y.** ✩, Goyal, S., . . . Master, V. A. (**2024**). Differences in preoperative frailty assessment of surgical candidates by sex, age, and race. *Surg Open Sci, 19*, 172-177. [Jun 2024; PMID: 38779040]
27. Kinney, B. L. C., Brammer, B., Kansal, V., Parrish, C. J., Kissick, H. T., **Liu, Y.** ✩, . . . Schmitt, N. C. (**2024**). CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent. *Oncoimmunology, 13*(1), 2367777. [Jun 2024; PMID: 38887372]
28. Carlisle, J., **Liu, Y.** ✩, & Leal, T. (**2024**). Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade. J Clin Oncol, Jco2400280. [Jul 2024; PMID: 38833649]
29. Guan, Y., McBride, C. M., Zhao, J., Pentz, R. D., Escoffery, C., **Liu, Y.** ✩, . . . Ward, K. C. (**2024**). Testing a Population-Based Outreach Intervention for Ovarian Cancer Survivors to Encourage their Close Relatives to Consider Genetic Counseling. Cancer Epidemiol Biomarkers Prev. [Jun 2024; PMID: 38912902]
30. Bilen, M. A., Vo, B. T., **Liu, Y.**, Greenwald, R., Davarpanah, A. H., McGuire, D., . . . Master, V. A. (**2024**). Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial. *Res Sq*. PMC11326393
31. Gillani, M., Rupji, M., Paul Olson, T. J., Balch, G. C., Shields, M. C., **Liu, Y.** ✩, & Rosen, S. A. (**2024**). Objective performance indicators during specific steps of robotic right colectomy can differentiate surgeon expertise. *Surgery*. PMID: 39025692
32. Gillani, M., Rupji, M., Paul Olson, T. J., Sullivan, P., Shaffer, V. O., Balch, G. C., . . . **Liu, Y.** ✩, Rosen, S. A. (**2024a**). Objective performance indicators differ in obese and nonobese patients during robotic proctectomy. *Surgery*. PMID: 39304451
33. Gillani, M., Rupji, M., Paul Olson, T. J., Sullivan, P., Shaffer, V. O., Balch, G. C., . . . **Liu, Y.** ✩, Rosen, S. A. (**2024b**). Objective Performance Indicators During Robotic Right Colectomy Differ According to Surgeon Skill. *J Surg Res, 302*, 836-844. PMID: 39241292
34. Saba, N. F., Chaudhary, R., Kirtane, K., Marra, A., Ekpenyong, A., McCook-Veal, A., . . . **Liu, Y.** ✩, Chung, C. H. (**2024**). Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis. *Clin Cancer Res*. PMID: 39167623

* Statistical Methodology: Non- Peer-Reviewed Manuscripts (Proceedings or Under Review).

1. **Liu, Y.**, Tighiouart, M., & Rogatko, A. (**2011**). Escalation with overdose control using time to toxicity data for cancer phase I clinical trials. *JSM proceedings, Biometrics Section. Alexandria, VA: American Statistical Association*. 4139-4151.
2. **Liu, Y**., Nickleach, D.,Lipscomb, J. (**2013**). Propensity Score Matching for Multiple Treatment Comparisons in Observational Studies. *The 59th World Statistics Congress proceeding.*
3. Nickleach D., **Liu Y.**, Shrewsberry A., Ogan K., Kim S., Wang Z. (**2013**). SAS® Macros to Conduct Common Biostatistical Analyses and Generate Reports. *SESUG: The Proceeding of the SouthEast SAS User Group*. <http://analytics.ncsu.edu/sesug/2013/PO-05.pdf>.
4. Zhang. C., Rupji, M., **Liu, Y.**, Kowalski, J. (**2017**). SAS® Macros for Time–Dependent Effects and Risk Factors on Survival. *SESUG: The Proceeding of the SouthEast SAS User Group*, paper AD-136-2017.
5. Zhang. C., Rupji, M., **Liu, Y.**, Kowalski, J. (**2018**). Two SAS® Macros on Backward Elimination in Firth’s penalized partial likelihood Approach: Firth’s Logistic and Cox Models. *SESUG: The Proceeding of the SouthEast SAS User Group*.

**GRANT SUPPORTS**

* Active Support or Newly Funded Support

Source of Funding: NIH: P01 CA257906-01 (PI: Fu)

Period of Activity: 6/1/2022 – 5/31/2027

Title: **Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)**

Role: Core Director (20% effort)

Source of Funding: NIH: R01CA272991 (PI: Yang)

Period of Activity: 6/1/2023 – 5/31/2028

Title:  **Real-Time Volumetric Imaging for Motion Management and Dose Delivery Verification**

Role: Co-Investigator (5% effort)

Source of Funding: NIH: 1R01CA275199 (PI: Paulos)

Period of Activity: 6/1/2023 – 5/31/2028

Title: **Machanisms of Durable Antitumor Immunity Mediated by PI3K-Targeted T cells**

Role: Co-Investigator (5% effort)

Source of Funding: NIH: 1R01CA262123 (PI: Shin)

Period of Activity: 6/1/2023 – 5/31/2028

Title:  **Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck**

Role: Co-Investigator (5% effort)

Source of Funding: NIH: 1R01CA266613 (PI: Kang)

Period of Activity: 2/1/2022 – 1/31/2027

Title: **Decoding and targeting saccharopine pathway in cancer metastasis**

Role: Core Director (5% effort)

Source of Funding: NIH: 1R01AI145231-02 (PI: Waller)

Period of Activity: 6/1/2020 – 5/31/2025

Title:  **Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (DAMPEN-CI)**

Role: Co-investigator (10% effort)

Source of Funding: NIH/NIHR: 1R01NR020154-01 (PI: Wells)

Period of Activity: 07/29/2021-05/31/2026

Title: **Implementing an Evidence-Based, Multilevel Intervention to Promote HPV Vaccination Among HIV-Positive Adults**

Role: Co-investigator (3% effort)

Source of Funding: DOD: HT94252310318 (Kissick)

Period of Activity: 04/2024-04/2026

Title:  **Defining the molecular basis for the immunogenicity of ADT-resistant locally advanced prostate tumors**

Role: Co-investigator (5% effort)

Source of Funding: NIH: 1R01CA284648 (PI: Zhou)

Period of Activity: 07/2023-06/2028

Title: **Targeting LKB1-Null Lung Adenocarcinoma with Innate Immune System**

Role: Co-investigator (5% effort)

Source of Funding: NIH: 1R01CA280069 (PI: Kissick)

Period of Activity: 04/2024-03/2029

Title: **Genetic Mechanisms Controlling Kidney Cancer Immune Escape**

Role: Co-investigator (5% effort)

Source of Funding: NIH: 1R37CA276317 (PI: Guan)

Period of Activity: 07/2023-04/2028

Title: **Evaluating an evidence-based family history screening program adapted to increase reach and uptake of screening for BRCA-associated cancers in rural public health clinics**

Role: Co-investigator (10% effort)

Source of Funding: NIH: 1R01CA287866 (PI: Lesinski)

Period of Activity: 02/2024-01/2029

Title: **Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer**

Role: Co-investigator (5% effort)

* Completed Support

Source of Funding: NIH: AR076089-01A1 (PI: Feldman)

Period of Activity: 07/01/20-06/30/23

Title: Improving Clinical Trial Recruitment and Outcome Measures in Bullous Pemphigoid

Role: Co-investigator (5% effort)

Source of Funding: NIH/NCI: 1U54CA260563 (I. Sanz)

Period of Activity: 9/30/2020 – 8/31/2023

Title: Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

Role: Co-investigator (10% effort)

Source of Funding: DoD: W81XWH2110213 (S. Kang)

Period of Activity: 09/01/2021-08/31/2023

Title: Krebs Cycle Signaling for Therapy of Metastatic Lung Cancer

Role: Co-investigator (3.6% effort)

Period of Activity: 08/01/2021-07/31/2023

Title: Investigation of Circulation Tumor Cell Clusters as Potential Biomarkers for Aggressive

Role: Co-investigator (10% effort)

Source of Funding: DoD: W81XWH1910840 (B. Olson)

Period of Activity: 09/30/2019-09/29/2022

Total Direct Cost: $384,615

Title: Targeting Rb loss using BET inhibition to reprogram the prostate tumor Microenvironment

Role: Co-investigator (2.3% effort)

Source of Funding: DoD (PI: Master)

Period of Activity: 06/01/20-05/31/23

Title: CD8 T-cell Infiltration as a Predictor of Renal Cancer Progression after Surgery

Role: Co-investigator (10% effort)

Source of Funding: NIH/NCI: 1R01CA245386-01A1 (S. Sun)

Period of Activity: 07/07/2020-06/30/2025

Title: c-Myc modulation and its implications in EGFR-targeted cancer therapy

Role: Co-investigator (3% effort)

Source of Funding: NIH: 1R01CA203928-01(PI: Wei Zhou)

Period of Activity: 04/01/17-03/31/22

Total Direct Cost: $228,750

Title: Targeted Inhibition of Ribosomal RNA Synthesis in LKB1-deficient Cancers

Role: Co-investigator (5% effort)

Source of Funding: US DEPARTMENT OF DEFENSE (PI: Jin-Tang, Dong)

Period of Activity: 08/15/2018-08/14/2021

Total Direct Cost: $922,183

Title: A novel regulator of cancer stem cell plasticity and its roles in prostate cancer

Role: Co-investigator (4% effort)

Source of Funding: NIH - NIAID (PI: Edmund K. Waller)

Period of Activity: 05/01/2019-04/30/2020

Total Direct Cost: $242,748

Title: A novel regulator of cancer stem cell plasticity and its roles in prostate cancer

Role: Co-investigator (3% effort)

Source of Funding: V Foundation for Cancer Research-V2015-005 (PI: Lauren McCullough)

Period of Activity: 11/1/2017-10/31/2019

Total Direct Cost: $200,000

Title: Breast adipose inflammation: epidemiology and outcomes in Black and White women diagnosed with breast cancer

Role: Co-investigator (4% effort)

Source of Funding: NIH: 5 R01 CA142858-04 (PI: A. Marcus)

Period of Activity: 03/01/11-02/29/16

Total Direct Cost: $201,275

Title: Control of Lung Cancer Invasion and Metastasis by Vimentin

Role: Co-investigator (3.7% effort)

Source of Funding: NIH: 1 R01 CA180805-01 (PI: Van Meir)

Period of Activity: 09/01/13-08/31/16

Total Direct Cost: $323,672

Title: Discovery of Chemical Probes for Uveal Melanoma

Role: Co-investigator (5.6% effort)

Source of Funding: PCORI: AD-12-11-4532(PI: M. Goodman)

Period of Activity: 07/01/13-12/31/17

Total Direct Cost: $2,154,946

Title: Targeted Inhibition of Ribosomal RNA Synthesis in LKB1-deficient Cancers

Role: Co-investigator (10% effort)

Source of Funding: Emory Health Sciences Center SYNERGY Award (PI: T. Gillespie)

Period of Activity: 10/1/16-9/30/17

Total Direct Cost: $100,000

Title: Advancing Cancer Screening and Early Detection among People Living with HIV (PLWH)

Role: Co-investigator (5% effort)

Source of Funding: Movember Foundation (PI: T. Gillespie)

Period of Activity: 03/01/16-02/28/19

Total Direct Cost: $1,200,000

Title: Prostate Survivorship Research Network – True NTH

Role: Co-investigator (10% effort)

Source of Funding: Pfizer (PI: Ron Feldman)

Period of Activity: 11/01/17-12/30/19

Total Direct Cost: $58,959

Title: Impact of Pruritus on Clinical and Biological Outcomes in Atopic Dermatitis

Role: Co-investigator (5% effort)

Source of Funding: Hematology/Oncology Pharmacy Association (PI: Harvey III)

Period of Activity: 01/01/19-12/31/20

Total Direct Cost: $49,312

Title: Phase II Evaluation of the Effect of 2 Versus 6 Hour Oxaliplatin Infusions on Neuropathy

Role: Co-investigator (5% effort)

Source of Funding: NIH/AID: 1R56AI145231-01 (PI: Waller)

Period of Activity: 05/01/19-04/30/21

Total Direct Cost: $242,750

Title: Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell trans

Role: Co-investigator (3% effort)

Source of Funding: NIH/NCI: 5R01CA140515-10 (PI: Chen)

Period of Activity: 08/01/19-07/31/20

Total Direct Cost: $244,535

Title: Metabolic rewiring by oncogenic BRAF V600E links ketogenesis pathway to BRAF-MEK1

Role: Co-investigator (5% effort)

Source of Funding: (PI: Rosen)

Period of Activity: 01/01/20-12/31/20

Total Direct Cost: $50,000

Title: Analysis of objective performance metrics during robotic-assisted colon and rectal surgery

Role: Co-investigator (5% effort)

**TEACHING/MENTORING ACTIVITIES**

* Course Instructor:

2017 Fall - **BIOS 500 Lab** – *Introduction to SAS programming*

2018 Spring- **BIOS 560R** - *Applied and Advanced Statistical Techniques in Observational Studies*

2020 Spring- **BIOS 560R** - *Applied and Advanced Statistical Techniques in Observational Studies* (Average score of evaluation: 4.5/5 for a class size of 33, response rate: 79% )

2022 Spring- **BIOS 530** - *Applied and Advanced Statistical Techniques in Observational Studies* (Average score of evaluation: 4.4/5 for a class size of 27, response rate 85%)

2024 Spring- **BIOS 530** - *Applied and Advanced Statistical Techniques in Observational Studies* (Average score of evaluation: **4.7/5** for a class size of 18, response rate 50%)

This BIOS 530 is driven by real-world experience and designed to cover the concepts and implementations of modern analytic methodologies and strategies in observational studies and to equip the students with essential tools and mindset to conduct an observational study for causal inference and prediction. Propensity score methods, modeling for prediction, risk stratification/validation, and the guidance of Good Research Practice will be illustrated along with real-life projects based on the National Cancer Database (NCDB) and backed up by the recent literature.

* Faculties Mentored:

Ma Tianwen – Research Assistant Professor (2022 -): Meet monthly to address any issues related to service core development.

Tarrant McPherson – Research Assistant Professor (2023 -): Meet every other two weeks to follow up on project progress and share ongoing thoughts and ideas in cancer collaborations.

* MPH/MSPH/MS Thesis Committee Chair:

Name: [Kelli O’Connell](mailto:kelli.oconnell@gmail.com)

Program: MSPH in Biostatistics 2016

Thesis: Propensity Score Matched Analysis to Compare the Effectiveness of Proton Therapy versus Photon-Based Radiation for Non-Small Cell Lung Cancer Patients Based on National Cancer Database (Peer-Reviewed Publication #22, 26; Conference Abstract #54, 58, 67)

Name: [Yaqi Jia](mailto:Yaqi%20Jia%20%3cjiayaqi1987@gmail.com%3e)

Program: MPH in Global Environmental Health 2016

Thesis: Stereotactic body radiotherapy (SBRT) vs. surgery in elderly early stage non-small Cell lung cancer patients (Conference Abstract #63, 69)

Name: [Wendi Liang](mailto:sunliangwendi@gmail.com)

Program: MSPH in Biostatistics 2016

Thesis: Analysis of Socioeconomic Disparities in Receipt of Adjuvant Chemotherapy in Stage II Colon Cancer: An Inquiry Based on National Cancer Database (Peer-Reviewed Publication #54; Conference Abstract #79)

Name: [Sun Qin](mailto:Kiki%20Sun%20%3ckikisun1688@gmail.com%3e)

Program: MPH in Biostatistics 2017

Thesis: Apocrine Carcinoma of the Breast: Treatment Patterns and Outcomes (Conference Abstract #78)

Name: [Alexandra Aiello](mailto:%20aaiello321@gmail.com%204404879912)

Program: MSPH in Biostatistics 2017

Thesis:  The Application of Generalized Propensity Score Approaches on Dichotomous, Continuous, and Ordinal Treatment to Analyze the Effect of Total Radiation Dose on Cervical Esophageal Cancer Survival (Conference Abstract #73).

Name: [Ao Jingning](mailto:Jingning.ao@gmail.com)

Program: MSPH in Biostatistics 2017

Thesis: A Propensity Score Analysis Exploring the Effect of Adjuvant Chemotherapeutic Agent with Radiation Therapy and Androgen Deprivation Therapy in Patients with High Risk Prostate Cancer (Peer-Reviewed Publication #37; Conference Abstract #76).

Name: [Lael Rayfield](mailto:Lael%20Rayfield%20%3clael.rayfield@gmail.com%3e)

Program: MS in Biostatistics 2017

Thesis: Prognostic Relevance of HPV Infection in Cases of Anal Squamous Cell Carcinoma: A Weighted Propensity Score Analysis See (Peer-Reviewed Publication #31, 38, Conference Abstract #88)

Name: [Xiting Zhu](mailto:xiting.zhu@hotmail.com)

Program: MPH in Biostatistics 2017

Thesis: Propensity Score Matched Analysis on Survival Profile of Head and Neck Cancer in the U.S. Hispanic Population (Conference Abstract #72)

Name: [Yizhao Xi](mailto:xiyizhao94@gmail.com)

Program: MSPH in Biostatistics 2018

Thesis: Assess Balance of Covariates after Propensity Score as Covariate Adjustment: SAS® macro Development and Application (Peer-Reviewed Publication #49, Conference Abstract #85, 91).

Name: [Haocan Song](mailto:haocan.song@gmail.com)

Program: MPH in Biostatistics 2018

Thesis: [Assess Improvement of Balancing Covariates by Propensity Score approach using Generalized Boosted Model (GBM) and Application Based on National Cancer Database](https://etd.library.emory.edu/concern/etds/k3569441r?locale=en).

Practicum: Comparison of the seventh and eighth editions of the American Joint Committee on Cancer (AJCC) staging for oropharyngeal squamous cell carcinomas (OPSCC): A Surveillance, Epidemiology and End Results Program (SEER) database analysis. (Conference Abstract #99 112)

Name: [Ruizhe Wu](mailto:ruizhw19@gmail.com)

Program: MPH in Biostatistics 2018

Thesis: Risk Stratification by Nomogram for Stage II Colon Cancer Patients and Impacts from Adjuvant Chemotherapy on Overall Survival Based on NCDB.

Name: Yiman Li

Program: MPH in Biostatistics 2019

Thesis: The impact of concurrent radiotherapy on overall survival among late-stage melanoma patients treated with immunotherapy.

Name: [Mengyu](mailto:ruizhw19@gmail.com) Di

Program: MPH in Biostatistics 2019

Thesis: The predictors for overall survival for small-cell lung cancer patients who treated by immunotherapy.

Name: [Chen](mailto:ruizhw19@gmail.com) Jiang

Program: MPH in Biostatistics 2019

Thesis: The role of adjuvant chest wall irradiation in intermediate risk breast cancer following mastectomy based on NCDB. (Peer-Reviewed Publication #115; Conference Abstract #10)

Name: [Yuxian](mailto:ruizhw19@gmail.com) Sun

Program: MPH in Biostatistics 2020

Thesis: Whether the proton beam radiation leads to lesssecondary malignancies among localized prostate cancer patients.

Name: Yuhan Ji

Program: MSPH in Biostatistics 2020

Thesis: Development and validation of risk stratification for metastasis prostate cancer patients.

Name: Ruowen Qi

Program: MSPH in Biostatistics 2020

Thesis: The impact of radiation to the primary tumor for newly diagnosed metastatic prostate cancer.

Name: Xueying Lyu

Program: MSPH in Biostatistics 2020

Thesis: Identify optimum subgroup who would benefit androgen blockade after salvage radiation therapy in prostate cancer.

Name: Xingyu Gao

Program: MSPH in Biostatistics 2021

Thesis: Explore the optimal condition of using propensity score method using the overlap coefficient of covariates.

Name: Mian Guo

Program: MSPH in Biostatistics 2021

Thesis: Using Machine Learning approach to identify the optimal treatment subgroup for breast cancer patient in receiving radiation.

Name: Feifei Geng

Program: MSPH in Biostatistics 2021

Thesis: Evaluation the OS difference among breast cancer patients who received SLND vs. ALND.

Name: Shirley Li

Program: MSPH in Biostatistics 2021

Thesis: The Log Odds of Positive Lymph Nodes (LODDS) Predicts Survival of Cervical cancer

Name: Sihong Li

Program: MSPH in Biostatistics 2022

Capstone: Comparing survival outcomes in men with localized prostate cancer who undergo radiation therapy with versus without treatment dela

Name: Chenbo Sun

Program: MSPH in Biostatistics 2022

Capstone: Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Different Radiation Subgroups

Name: Zelin Wang

Program: MSPH in Biostatistics 2022

Capstone: Evaluating the use of the surgery as primary recommended treatment for localized, high-risk prostate cancer before and after 2012

* MPH/MSPH/MS Thesis Committee Member:

Name: Juhee Lee

Program: MPH in Biostatistics 2010

Chair: Limin Peng

Thesis: Application of Competing Risks Quantile Regression for the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Study.

Name: Wei Li

Program: MPH in Biostatistics 2014

Chair: Limin Peng

Thesis: Exploring Risk Factors for Vitamin D Deficiency in Cystic Fibrosis Patients and Generally healthy Population

Name: Benjamin J. Flink

Program: MPH in Global Health 2015

Chair: Roger Rochat

Thesis: Disparities in Pancreatic Adenocarcinoma Care Using the National Cancer Data Base

Name: Samuel M. Hyde

Program: MMS in Human Genetics & Genetic Counseling 2015

Advisor: Theresa Gillespie

Thesis: From Mendel’s Peas to Applications-Based Genetics: A Novel High School Education Intervention Aimed at Increasing Understanding of Health-Related Genetics and Genomics

Name: Kushal Naik

Program: MPH in Epidemiology 2016

Chair: Michael Goodman

Thesis: Chemo-Radiation With or Without Surgery for Resectable Esophageal Cancer: An Analysis of Survival among 11,122 Patients in the National Cancer Data Base (NCDB) (Peer-Reviewed Publication #29, Conference Abstract #61)

Name: Hiba Z. Ahmed

Program: MPH in Global Epidemiology 2017

Chair: Kristin Higgins, Michael Goodman

Thesis: Guideline Concordant Care Improve Overall Survival for Locally Advanced Non-Small Cell Lung Carcinoma Patients: A National Cancer Data Base Analysis (Peer-Reviewed Publication #26, Conference Abstact #67)

Name: Shuo Wang

Program: MPH in Epidemiology 2018

Chair: Theresa Gillespie

Thesis: [Effect of Surgical Margins on Overall Survival in Resectable Pancreatic Cancer](https://etd.library.emory.edu/concern/etds/3484zg951?locale=en).

* MPH/MSPH/PHD Student Practicum Supervisor

Name: Priti Shah

Program: MPH in Epidemiology 2017

Chair: Michael Goodman

Thesis: Follow up Imagine and Survival in Head and Neck Cancer Patients

Name: Fu Chao

Program: MPH in Epidemiology 2015

Projects: Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base (Peer-Reviewed Publication #28, 55, Conference Abstract #44, 80)

Name: Michael Mengyeh Yuan

Program: MPH in Epidemiology 2016

Projects: Squamous Cell Carcinoma of Lung in the United States: Analysis of the National Cancer Database (NCDB) (Conference Abstract #45)

Name: [Xi Liu](mailto:xi%20liu%20%3cliuxifdu@gmail.com%3e)

Program: MPH in Epidemiology 2016

Projects: The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer (Peer-Reviewed Publication #25; Conference Abstract # 51, 66)

Name: Chuqing Chen

Program: MPH in Epidemiology 2016

Projects: Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor (Peer-Reviewed Publication #30; Conference Abstract #52)

Name: [Zixun Ye](mailto:zxye37@gmail.com)

Program: MPH in Biostatistics 2017

Projects: Cognitive Impairment and Overall Survival in Frail Surgical Patients (Peer-Reviewed Publication #95)

Name: [Na Bo](mailto:bona930201@gmail.com)

Program: MPH in Biostatistics 2017

Projects: Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab (Peer-Reviewed Publication #96)

Name: En Cheng

Program: MPH in Epidemiology 2017

Projects: Proton vs. Photon Radiation Therapy for Primary Gliomas: An Analysis of the National Cancer Data Base (Peer-Reviewed Publication #40; Conference Abstract #70)

Name: Xi Sheng

Program: MPH in Epidemiology 2017

Projects: The Utilization and Overall Survival of Transanal Local Excision for Stage I Rectal Cancer Persist Compared to Standard Resection: A Retrospective Study Based on the National Cancer Database (Peer-Reviewed Publication #47; Conference Abstract #77)

Name: Minxuan Huang

Program: PhD in Epidemiology 2017

Projects: Epidemiology and Prognosis of Gallbladder Cancer: an Analysis of the National Cancer Data (Manuscript submitted).

Name: Alyssa Nicole Troeschel

Program: PhD in Epidemiology 2017

Projects: Racial/ethnic differences in all-cause and cause-specific mortality patterns among a cohort of invasive US breast cancer patients. (Peer-Reviewed Publication #43).

Name: [Julian Zhao](mailto:zhaoxiwen2015@gmail.com)

Program: MPH in Biostatistics 2018

Projects: Defining Clinical Severity and Treatment Responses in a Historical Cohort of Patients with Bullous Pemphigoid. (Peer-Reviewed Publication #96).

Name: Chen Jiang

Program: MPH in Biostatistics 2019

Projects: New or Worsening Immune-Related Adverse Events with Long-Term Use of

PD-1 and PD-L1 Checkpoint Inhibitors.

Name: Niya Xiong

Program: MSPH in Biostatistics 2019

Projects: Early Post-Treatment Mortality after Surgery and SBRT for Early-Stage NSCL

Name: Tao Liang

Program: MSPH in Biostatistics 2019

Projects: The impact of Proton Therapy on Overall Survival among Breast Cancer Patients: A NCDB

Based Study.

Name: He Jinjing

Program: MSPH in Biostatistics 2020

Projects: Breast adipose inflammation: epidemiology and outcomes in Black and White women diagnosed with breast cancer

Name: Yuxian Sun

Program: MSPH in Biostatistics 2020

Projects: Impact of Pruritus on Clinical and Biological Outcomes in Atopic Dermatitis

Name: Mingrui Zhang

Program: MSPH in Biostatistics 2020

Projects: Matching generalized propensity score software development

Name: Feng Tian

Program: MSPH in Biostatistics 2020

Projects: SAS Macro Development for Propensity Score Balance Check

Name: Limeng Wan

Program: MSPH in Biostatistics 2021

Projects: Outcomes in docetaxel (DOC) vs. abiraterone (ABI) in castration sensitive prostate cancer

Name: Xiaobo Yan

Program: MSPH in Biostatistics 2021

Projects: Impact of Pruritus on Clinical and Biological Outcomes in Atopic Dermatitis

Name: Kexin Guan

Program: MSPH in Biostatistics 2022

Projects: Second Tumor in Prostate Cancer among Patients who received Radiation

Name: Anyue Ruan

Program: MSPH in Biostatistics 2023

Projects: Mimic clinical trial using Large scale of observational database in lung cancer

Name: Han Xu

Program: MSPH in Biostatistics 2023

Projects: Mimic clinical trial using Large scale of observational database in breast cancer

Name: Shannon Lu

Program: MSPH in Biostatistics 2023

Projects: Mimic clinical trial using Large scale of observational database in prostate cancer

Name: Weiding Fang

Program: MSPH in Biostatistics 2023

Projects: SAS macro development for streamlined data analyses with a professional report.

Name: Sarah Kulkarni

Program: MSPH in Biostatistics 2024

Projects: 1. Post-radiation Secondary Tumor rate by different radiation modalities – an NCDB-based investigation. 2. Post-Mastectomy Radiation Therapy for Intermediate-Risk Breast Cancer Patients with 0-3 Positive Axillary Lymph Nodes: Emulating the SUPREMO Trial Using Real-World Data

Name: Mengting Wei

Program: MSPH in Biostatistics 2024

Projects: 1. Risk Stratification by Common Lab Values for Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated by Immunotherapy. 2. Association of Baseline Inflammatory Biomarkers and Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Name: Shuyang Yue

Program: MSPH in Biostatistics 2024

Projects: SAS Macro Development for GEE modeling and Application on Clinical Trial Data

Name: Yixin Chen

Program: MSPH in Biostatistics 2024

Projects: 1. Emulate Z0011 Clinical Trial Using Large Scale of Observational Databases: Opportunities and Challenges. 2. Clinical observational study utilizing teledermatology in bullous pemphigoid; 3. Increasing trends in morbidity, mortality, and hospitalizations in African American patients in the Southeast: a descriptive retrospective chart review

* National Cancer Data Base Training Workshop: Course Director

**Aug - Nov 2015** at Emory University - This short course was designed to help clinical PIs get familiar with the National Cancer Database, know its advantages and limitations, and provide a step-by-step guide to starting the research by following a collaborative workflow. The second part of the workshop focused on the analytic workflow by using SAS@ macros and report template, which was aimed at students/trainees who need to conduct their own data analysis based on NCDB. There were a total of **50** participants. A new session will be planned in the near future.

* Other Teaching

2015-2017 served as speaker for the topic “Observational Study Designs in Medical Research.” at the oncology reviews journal club at Winship Cancer Institute.

2017-2019 lecture to undergraduate students from the Summer Institute for Training in Biostatistics (SIBS)

2020-2023 Speaker of Statistics for Cancer Biomarker at Winship K12 Intensive Skill Building and Orientation Workshop.

* Other Mentorship

2016-2017 served as a mentor for Dr. Youxi Luo, a visiting professor from Hubei University of Technology, Wuhan, China.

2016 -2016 served as a mentor for Da Feng, a visiting Ph.D. student from Huazhong University of Science and Technology, Wuhan, China.

**PROFESSIONAL SERVICE ACTIVITIES**

2018 – Committee member in MSPH/MPH admission committee, diversity committee, and curriculum committee in the Department of Biostatistics and Bioinformatics at Emory University.

2021- 2024 Department Representative to Research Advisory Committee at Rollins School of Public Health at Emory University.

**SOFTWARE DEVELOPMENT**

Logo, company name

Description automatically generatedSAS Macros for routine data analyses with the professional report (2011 ~ current): Served as the leading effort for developments and updates. These are a series of high-performance tools that cover the entire analytic streamline of data analysis and produce journal-quality summary tables, including descriptive statistics, univariate associations, multivariable models, subgroup analyses, and data visualization. Those macros have significantly increased our core capabilities and are routinely used in our daily data analysis projects. See publication PMID: [31231506](https://pubmed.ncbi.nlm.nih.gov/31231506) for more details.

SAS Macros for propensity score-related implementation (2011 ~ current): Served as the leading effort for developments and updates. Three SAS macros were developed to calculate the propensity score (PS) for binary or categorical treatment comparison groups, to match or weight the treatments by PS, and to examine the covariate balance after PS implementation. The macros carry out essential steps during the execution of a PS approach and generate professional summary reports and plots to be used in the manuscript directly.

SAS Macros for clinical trial data analyses (2020 ~ Current): Served as the senior mentor for validating sequential SAS Macro tools for commonly requested analyses: adverse events summary table, swimming plot, waterfall plot, spider plots, and forest plots.

R Function/Package for Propensity Score Matching for multiple treatments: To conduct propensity score matching for more than two treatment options using generalized propensity scores. It carries a locally optimal matching in the high-dimensional space formed by GPS with a bounded computational burden (See Bibliography #8). In a recent development, an R package has been underway.

**PROFESSIONAL AFFILIATIONS**

2004 – Present Member of the American Statistical Association

2009 – Present Member of the Society for Clinical Trials

2013 – Present Member of the International Statistical Institute

**OTHER TRAINING**

2020-2021 Team Science Workshops - Georgia Clinical & Translational Science Alliance

2021 – Foundations of Everyday Leadership – Online course by the University of Illinois at Urbana-Champaign

**HONORS/AWARD**

2019 RSPH Supervisor Award

2019 Biostatistics Faculty Mentor Award

2013 American Statistical Association Travel Grant award for attending the 59th ISI conference.